Angiotensin-(1–7) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism
Open accessThe DOI matches its Crossref record; 66 of the 69 references it cites were found in a registry or an index.
Abstract
Skeletal muscle atrophy is a pathological condition characterized by the loss of strength and muscle mass, an increase in myosin heavy chain (MHC) degradation and increase in the expression of two muscle-specific ubiquitin ligases: atrogin-1 and MuRF-1. Angiotensin II (AngII) induces muscle atrophy. Angiotensin-(1–7) [Ang-(1–7)], through its receptor Mas, produces the opposite effects than AngII. We assessed the effects of Ang-(1–7) on the skeletal muscle atrophy induced by AngII. Our results show that Ang-(1–7), through Mas, prevents the effects induced by AngII in muscle gastrocnemius: the decrease in the fibre diameter, muscle strength and MHC levels and the increase in atrogin-1 and MuRF-1. Ang-(1–7) also induces AKT phosphorylation. In addition, our analysis in vitro using C2C12 myotubes shows that Ang-(1–7), through a mechanism dependent on Mas, prevents the decrease in the levels of MHC and the increase in the expression of the atrogin-1 and MuRF-1, both induced by AngII. Ang-(1–7) induces AKT phosphorylation in myotubes; additionally, we demonstrated that the inhibition of AKT with MK-2206 decreases the anti-atrophic effects of Ang-(1–7). Thus, we demonstrate for the first time that Ang-(1–7) counteracts the skeletal muscle atrophy induced by AngII through a mechanism dependent on the Mas receptor, which involves AKT activity. Our study indicates that Ang-(1–7) is novel molecule with a potential therapeutical use to improve muscle wasting associated, at least, with pathologies that present high levels of AngII.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Regarding skeletal muscle, there is broad evidence about the antiatrophic and antisarcopenic role of Ang-(1-7) [141–144].”
From The critical role of oxidative stress in sarcopenic obesity (2021) · cites this paper as [141]
Citations
Cites
1 retracted
Lokireddy, S., McFarlane, C., Ge, X., Zhang, H., Sze, S. K., Sharma, M., & Kambadur, R. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1124 · Cited by 117
RetractedIdentification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964
Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
Santos, R. A. S., e Silva, A. C. S., Maric, C., Silva, D. M. R., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V. B., Lopes, M. T., Bader, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432869100 · Cited by 1,801
Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy
Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A., & Goldberg, A. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251541198 · Cited by 1,774
Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583
Cellular and molecular mechanisms of muscle atrophy
Bonaldo, P., & Sandri, M. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.010389 · Cited by 1,284
The Molecular Basis of Skeletal Muscle Atrophy
Jackman, R. W., & Kandarian, S. C. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00579.2003 · Cited by 1,008
Cited by
The ACE2/angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)
Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., & Campagnole-Santos, M. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2016 · Cited by 1,144
Renin‐Angiotensin System: An Old Player with Novel Functions in Skeletal Muscle
Cabello‐Verrugio, C., Morales, M. G., Rivera, J. C., Cabrera, D., & Simon, F. (2015) · Medicinal Research Reviews · doi:10.1002/med.21343 · Cited by 165
Self-citationAbrigo, J., Rivera, J. C., Aravena, J., Cabrera, D., Simon, F., Ezquer, F., Ezquer, M., & Cabello-Verrugio, C. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9047821 · Cited by 109
“Fibers were handled manually, and the minimal Feret diameter of each fiber was computed by the software [28, 29].”
Self-citationKarnik, S. S., Singh, K. D., Tirupula, K., & Unal, H. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13742 · Cited by 105
“…production of TGF-β1 and collagen in cardiac fibroblasts (Meng et al., 2014; Tao et al., 2014; Zheng et al., 2015a), muscle atrophy of gastrocnemius (Cisternas et al., 2014), pancreatic cell damage (Wang et al., 2014), ICAM-1, VCAM-1, and MCP-1 expression in HUVECs (Liang et al., 2015a,b) is…”
BackgroundAngiotensins as therapeutic targets beyond heart disease
Passos-Silva, D. G., Brandan, E., & Santos, R. A. S. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.001 · Cited by 99
Self-citationFibrosis development in early-onset muscular dystrophies: Mechanisms and translational implications
Serrano, A. L., & Muñoz-Cánoves, P. (2017) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.09.013 · Cited by 94
The critical role of oxidative stress in sarcopenic obesity
Gonzalez, A., Simon, F., Achiardi, O., Vilos, C., Cabrera, D., & Cabello-Verrugio, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/4493817 · Cited by 79
Self-citationAngiotensin-(1-7) attenuates disuse skeletal muscle atrophy via the Mas receptor
Morales, M. G., Abrigo, J., Acuña, M. J., Santos, R. A., Bader, M., Brandan, E., Simon, F., Olguin, H., Cabrera, D., & Cabello-Verrugio, C. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.023390 · Cited by 77
“Our group recently demonstrated that Ang-(1-7), the main peptide of non-classical RAS, has an opposing role to Ang II in cachexia (Cisternas et al., 2015; Meneses et al., 2015).”
BackgroundMethodResultInfluentialSelf-citationFrantz, E. D. C., Prodel, E., Braz, I. D., Giori, I. G., Bargut, T. C. L., Magliano, D. C., & Nobrega, A. C. L. (2018) · Clinical Science · doi:10.1042/cs20180276 · Cited by 75
Lv, J., Li, Y., Shi, S., Xu, X., Wu, H., Zhang, B., & Song, Q. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113833 · Cited by 80
Henríquez‐Olguín, C., Boronat, S., Cabello‐Verrugio, C., Jaimovich, E., Hidalgo, E., & Jensen, T. E. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7678 · Cited by 76
“For instance, Ang-II, suggested to induce muscle atrophy via NOX2 (4, 63), also caused insulin resistance in incubated rat soleus muscles via a mechanism partially alleviated by the antioxidant tempol (84).”
BackgroundSelf-citationMolecular mechanisms of cancer cachexia‑induced muscle atrophy (Review)
Yang, W., Huang, J., Wu, H., Wang, Y., Du, Z., Ling, Y., Wang, W., Wu, Q., & Gao, W. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11608 · Cited by 70
Ábrigo, J., Rivera, J. C. A., Simón, F., Cabrera, D., & Cabello‐Verrugio, C. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.01.010 · Cited by 69
Self-citationMorales, M. G., Olguín, H., Di Capua, G., Brandan, E., Simon, F., & Cabello-Verrugio, C. (2015) · Clinical Science · doi:10.1042/cs20140840 · Cited by 62
Self-citationThe Renin-Angiotensin System and Skeletal Muscle
Powers, S. K., Morton, A. B., Hyatt, H. W., & Hinkley, J. M. (2018) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000158 · Cited by 70
ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19
Yamamoto, K. I., Takeshita, H., & Rakugi, H. (2020) · Clinical Science · doi:10.1042/cs20200486 · Cited by 63
Campos, F., Ábrigo, J., Aguirre, F. S., Garcés, B., Arrese, M. A., Karpen, S. J., Cabrera, D., Andía, M. E., Simón, F., & Cabello‐Verrugio, C. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2167-3 · Cited by 56
Self-citation20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor
Lafont, R., Serova, M., Didry-Barca, B., Raynal, S., Guibout, L., Dinan, L., Veillet, S., Latil, M., Dioh, W., & Dilda, P. J. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-21-0033 · Cited by 50
Frantz, E. D. C., Giori, I. G., Machado, M. V. R., Magliano, D. C., Freitas, F. M., Andrade, M. S. B., Vieira, A. B., da Nóbrega, A. C. L., & Tibiriçá, E. V. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00078.2017 · Cited by 49
Takeshita, H., Yamamoto, K. I., Nozato, S., Takeda, M., Fukada, S., Inagaki, T., Tsuchimochi, H., Shirai, M., Nozato, Y., Fujimoto, T., et al. (2018) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12334 · Cited by 49
Effect of renin–angiotensin system on senescence
Mogi, M. (2020) · Geriatrics & Gerontology International · doi:10.1111/ggi.13927 · Cited by 48
Mas Receptor Activation Slows Tumor Growth and Attenuates Muscle Wasting in Cancer
Murphy, K. T., Hossain, M. I., Swiderski, K., Chee, A., Naim, T., Trieu, J., Haynes, V. R., Read, S. J., Stapleton, D., Judge, S. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1207 · Cited by 51
“The two regulatory axes of the RAS exert opposing effects in several tissues including skeletal muscle (31, 32), with the "classical" ACE/Ang II/AT1 axis inducing muscle wasting, which can be counteracted by the "alternative" ACE2/Ang-(1-7)/MasR axis (9, 10, 15).”
BackgroundInfluentialAngiotensin (1-7) Decreases Myostatin-Induced NF-κB Signaling and Skeletal Muscle Atrophy
Aravena, J., Ábrigo, J., González, F., Aguirre, F. S., González, A., Simón, F., & Cabello‐Verrugio, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031167 · Cited by 44
“As Ang-(1-7) is able to activate Akt phosphorylation in the C2C12 myotubes [26], we evaluated if the effects of Ang-(1-7) on the myostatin-dependent atrophy and signaling were dependent on the Akt activity.”
BackgroundMethodInfluentialSelf-citationN-Acetyl Cysteine Attenuates the Sarcopenia and Muscle Apoptosis Induced by Chronic Liver Disease
Ábrigo, J., Marín, T., Aguirre, F. S., Tacchi, F., Vilos, C., Simón, F., Arrese, M. A., Cabrera, D., & Cabello‐Verrugio, C. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666190917124636 · Cited by 42
Self-citationNozato, S., Yamamoto, K., Takeshita, H., Nozato, Y., Imaizumi, Y., Fujimoto, T., Yokoyama, S., Nagasawa, M., Takeda, M., Hongyo, K., et al. (2019) · Clinical Science · doi:10.1042/cs20190573 · Cited by 37
Therapeutic approaches targeting renin-angiotensin system in sepsis and its complications
Ning, L., Rong, J., Zhang, Z., & Xu, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105409 · Cited by 36
Ábrigo, J., Simon, F., Cabrera, D., & Cabello-Verrugio, C. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000452522 · Cited by 35
Self-citationBIO101 stimulates myoblast differentiation and improves muscle function in adult and old mice
Serova, M., Didry‐Barca, B., Deloux, R., Foucault, A., Veillet, S., Lafont, R., Dilda, P. J., & Latil, M. (2024) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13326 · Cited by 35
González, A., Orozco-Aguilar, J., Achiardi, O. A., Simón, F., & Cabello‐Verrugio, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217904 · Cited by 41
“Both conditions, increases in Ang II/AT1R and decreases in ACE2/Ang-(1-7), have been identified in other chronic diseases, such as CVD and T2DM, and could happen in SARS-CoV-2 [18,25,38] (Figure 2).”
BackgroundInfluentialSelf-citationSkeletal muscle wasting: new role of nonclassical renin–angiotensin system
Cabello‐Verrugio, C., Rivera, J. C. A., & García, D. (2017) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000361 · Cited by 37
Self-citationEccentric Overload Muscle Damage is Attenuated By a Novel Angiotensin- (1-7) Treatment
Becker, L. K., Totou, N. L., de Moura, S. S., Kangussu, L. M., Millán, R. D. S., Campagnole‐Santos, M. J., Coelho, D. B., Motta‐Santos, D., & Santos, R. A. (2018) · International Journal of Sports Medicine · doi:10.1055/a-0633-8892 · Cited by 33
Protective Effect of Angiotensin 1–7 on Sarcopenia Induced by Chronic Liver Disease in Mice
Aguirre, F. S., Ábrigo, J., González, F., González, A., Simón, F., & Cabello‐Verrugio, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113891 · Cited by 32
“Even though these pathways were not evaluated in this paper, we have previously described that Ang-(1-7) can downregulate the NF-κB, FoxO and also activate the pathway IGF-1/IGFR/PKB/ mTOR/p70S6K [22,23].”
BackgroundSelf-citationRivera, J. C. A., Ábrigo, J., Tacchi, F., Simón, F., Brandan, E., Santos, R. A. S., Bäder, M., Chiong, M., & Cabello‐Verrugio, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249344 · Cited by 32
“Interestingly, Ang-(1-7) possesses anti-atrophic effects via Mas receptor activation [24,25].”
BackgroundSelf-citationKwon, O. S., Smuder, A. J., Wiggs, M. P., Hall, S. E., Sollanek, K. J., Morton, A. B., Talbert, E. E., Toklu, H. Z., Tümer, N., & Powers, S. K. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00237.2015 · Cited by 32
Márquez‐Miranda, V., Ábrigo, J., Rivera, J. C. A., Araya‐Durán, I., Aravena, J., Simón, F., Pacheco, N., González-Nilo, F. D., & Cabello‐Verrugio, C. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s125521 · Cited by 33
Self-citationTherapeutic uses for Angiotensin-(1-7)
Machado-Silva, A., Passos-Silva, D. G., Santos, R. A. S., & Sinisterra, R. D. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1179283 · Cited by 33
Vasileiadis, I. E., Goudis, C. A., Giannakopoulou, P., & Liu, T. (2018) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2018.1432034 · Cited by 30
Li, W., Qin, X., Poon, C. C., Wong, M., Feng, R., Wang, J., Lin, F., Sun, Y., Liu, S., Wang, Y., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4441 · Cited by 31
“MAFbx promotes the degradation of MyoD, a key muscle transcription factor regulating myoblast transition from proliferation to differentiation, and MURF1 acts on the protein substrate MHC, one of the sarcomeric proteins, to accelerate muscle proteolysis.((26,28)) This study delineated that ARB successfully suppressed…”
BackgroundWestermeier, F., Bustamante, M., Pávez, M., García, L., Chiong, M., Ocaranza, M. P., & Lavandero, S. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.018 · Cited by 26
“[107] F.”
BackgroundPharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers?
Sartiani, L., Spinelli, V., Laurino, A., Blescia, S., Raimondi, L., Cerbai, E., & Mugelli, A. (2015) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2015.12.2.135 · Cited by 27
Fu, W. D., Guan, L., Liu, Q., Xie, Z., You, J., & Chen, R. (2025) · European Respiratory Review · doi:10.1183/16000617.0069-2025 · Cited by 27
“In contrast, the non-classical RAS pathway counteracts the effects of the classical pathway [153].”
Cao, C., Hasegawa, Y., Hayashi, K., Takemoto, Y., & Kim‐Mitsuyama, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181000 · Cited by 24
González, A., Ábrigo, J., Achiardi, O. A., Simón, F., & Cabello‐Verrugio, C. (2022) · European Journal of Translational Myology · doi:10.4081/ejtm.2022.10511 · Cited by 22
Self-citationAbrigo, J., Morales, M. G., Simon, F., Cabrera, D., Capua, G. D., & Cabello-Verrugio, C. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.06.011 · Cited by 20
Self-citationTakeshita, H., Yamamoto, K. I., Mogi, M., Nozato, S., Horiuchi, M., & Rakugi, H. (2019) · Hypertension Research · doi:10.1038/s41440-019-0375-7 · Cited by 17
Angiotensin 1‐7 protects against ventilator‐induced diaphragm dysfunction
Yoshihara, T., Deminice, R., Hyatt, H. W., Ozdemir, M., Nguyen, B. L., & Powers, S. K. (2021) · Clinical and Translational Science · doi:10.1111/cts.13015 · Cited by 18
Muscle wasting: A review of exercise, classical and non‐classical RAS axes
Winslow, M. A., & Hall, S. E. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14412 · Cited by 19
Renin angiotensin system-induced muscle wasting: putative mechanisms and implications for clinicians
Afsar, B., Afsar, R. E., Caliskan, Y., Lentine, K. L., & Edwards, J. C. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05043-8 · Cited by 15
“On the contrary, Cisternas et al. showed that skeletal muscle atrophy induced by AngII is reversed by Ang (1–7) via Mas receptor through decreased atrogin-1 and MuRF-1 expression and increased Akt phosphorylation [24].”
Annoni, F., Moro, F., Caruso, E., Zoerle, T., Taccone, F. S., & Zanier, E. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841692 · Cited by 16
Zambelli, V., Sigurtà, A., Rizzi, L., Zucca, L., Delvecchio, P., Bresciani, E., Torsello, A., & Bellani, G. (2019) · Intensive Care Medicine Experimental · doi:10.1186/s40635-018-0218-x · Cited by 16
Takeshita, H., Yamamoto, K. I., Mogi, M., Nozato, S., & Rakugi, H. (2023) · Hypertension Research · doi:10.1038/s41440-023-01189-y · Cited by 12
20-Hydroxyecdysone activates the protective arm of the renin angiotensin system via Mas receptor
Lafont, R., Raynal, S., Serova, M., Didry-Barca, B., Guibout, L., Latil, M., Dilda, P. J., Dioh, W., & Veillet, S. (2020) · doi:10.1101/2020.04.08.032607 · Cited by 11
de Moura, S. S., Mendes, A. T. P., Júnior, F. D. A. D. M., Totou, N. L., Coelho, D. B., de Oliveira, E. C., Motta‐Santos, D., Santos, R. A. S., & Becker, L. K. (2021) · BMC Sports Science Medicine and Rehabilitation · doi:10.1186/s13102-021-00274-4 · Cited by 11
“Participants received either the formulation of HPβ-CD-Placebo or the HPβ-CD-Ang-(1-7) (1.”
BackgroundMethodInfluentialCofré, C., Acuña, M. J., Contreras, O., Morales, M. G., Riquelme, C. A., Cabello‐Verrugio, C., & Brandan, E. (2015) · BioFactors · doi:10.1002/biof.1208 · Cited by 10
“Ang-(1–7) induces phosphorylation of AKT [31].”
BackgroundSelf-citationde Oliveira, E. C., Becker, L. K., Totou, N. L., Oliveira, M., Coelho, D. B., Motta‐Santos, D., Garcia, E. S., Campagnole‐Santos, M. J., & Santos, R. S. (2019) · The Chinese Journal of Physiology · doi:10.4103/cjp.cjp_57_19 · Cited by 10
“[5-7] In contrast, angiotensin-(1-7) (Ang-[1-7]) minimizes the muscle wasting effects of Ang II through the ubiquitin–proteasome pathway signaling, as well as by maintaining myosin heavy-chain protein levels.[2] In addition, Ang-(1-7), through Mas receptor, attenuates skeletal muscle atrophy and prevents insulin resis…”
BackgroundInfluentialAngiotensin-(1-7) improves skeletal muscle regeneration
Valero‐Breton, M., Tacchi, F., Ábrigo, J., Simón, F., Cabrera, D., & Cabello‐Verrugio, C. (2023) · European Journal of Translational Myology · doi:10.4081/ejtm.2023.12037 · Cited by 15
“8,9 In several pathologic states, such as chronic heart failure and chronic kidney failure, muscle wasting has been observed concomitantly with increased levels of Ang-II.”
BackgroundInfluentialSelf-citationStilhano, R. S., Samoto, V. Y., Silva, L. M., Pereira, G. J. S., Erustes, A. G., Smaili, S. S., & Han, S. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186719 · Cited by 10
Sanz, B., Rezola‐Pardo, C., Arrieta, H., Fernández‐Atutxa, A., Lora-Diaz, I., Goikouria, J. G., Rodriguez‐Larrad, A., & Irazusta, J. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111655 · Cited by 9
Genetic deletion of the Angiotensin-(1–7) receptor Mas leads to a reduced ovulatory rate
Honorato-Sampaio, K., Andrade, R. F., Bader, M., Martins, A. D. S., Santos, R. A. S., & Reis, A. M. (2018) · Peptides · doi:10.1016/j.peptides.2018.08.007 · Cited by 9
“IGF-1 promotes antiapoptotic effects on granulosa cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway [21,22,37], which inhibits BCL-2 family member BAD [38] and Caspase 9 [39], turning off the intrinsic apoptotic machinery [40] and promoting follicular survival.”
Influentialde Faria, M. H. S., Nunes-Silva, A., Marcucci-Barbosa, L. S., Barroso, L. S. S., de Barros, J. L. V. M., Kakehasi, A. M., Vieira, É. L. M., & Silva, A. C. S. E. (2021) · Sport Sciences for Health · doi:10.1007/s11332-021-00773-4 · Cited by 7
“Interestingly, in recent years, many studies have proposed that ACE2-Ang-(1–7)-Mas receptor axis exerts beneficial effects in skeletal muscle, including improvement in insulin sensitivity [25] and protection against muscle atrophy [26].”
Totou, N. L., de Moura, S. S., Júnior, F. D. A. D. M., Sousa, F. B. D., Coelho, D. B., de Oliveira, E. C., Santos, R. A. S., Becker, L. K., & de Lima, W. G. (2021) · Experimental Physiology · doi:10.1113/ep089308 · Cited by 7
“…have beneficial effects in skeletal muscle (Cabello-Verrugio et al., 2017; Echeverría-Rodríguez et al., 2014), such as improvement in insulin sensitivity (Echeverría-Rodríguez et al., 2014;Giani et al., 2009;Muñoz et al., 2010) and anti-atrophic factor (Abrigo et al., 2016; Cisternas et al., 2015).”
BackgroundSigurtà, A., Zambelli, V., & Bellani, G. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.07.013 · Cited by 7
Ang-(1–7) protects skeletal muscle function in aged mice
Li, Y., Song, J., Jiang, Y., Yang, X., Cao, L., Xiao, C. Y., Li, S., Dong, B., & Huang, X. (2021) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-021-04693-9 · Cited by 6
Fuloria, S., Subramaniyan, V., Meenakshi, D. U., Sekar, M., Chakravarthi, S., Kumar, D. H., Kumari, U., Vanteddu, V. G., Patel, T. D., Kishore, N., et al. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23030 · Cited by 12
Takeshita, H., Yamamoto, K. I., Mogi, M., Wang, Y., Nozato, Y., Fujimoto, T., Yokoyama, S., Hongyo, K., Nakagami, F., Akasaka, H., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.021030 · Cited by 6
Role of the renin-angiotensin-aldosterone system in sepsis and its therapeutic targets
Chen, X., Shao, M. L., Liu, Y., Zhou, J., Cao, F., Liu, Y., Qiu, G., Jiang, T., Huang, M., & Zhang, L. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115192 · Cited by 5
dos Santos, D. C., Alves, F. H. F., Veríssimo, L. F., Raquel, H. D. A., Volpini, V. L., Marques, L. A. D. C., Martins‐Pinge, M. C., Fernandes, K. B. P., Andrade, K. C., Michelini, L. C., et al. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105699 · Cited by 4
Järve, A., Qadri, F., Todiraş, M., Schmolke, S., Alenina, N. V., & Bäder, M. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00203 · Cited by 4
“Mas activation on the other hand counteracts skeletal muscle atrophy induced by Ang II (Cisternas et al., 2015), disuse (Morales et al.”
BackgroundMuscle mass, muscle strength and the renin-angiotensin system
Takeshita, H., Yamamoto, K. I., Mogi, M., & Rakugi, H. (2024) · Clinical Science · doi:10.1042/cs20220501 · Cited by 4
Acuña, M. J., Brandan, E., & Motta‐Santos, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-22696-1_11 · Cited by 5
Self-citationAngiotensin 1–7 increases fiber cross-sectional area and force in juvenile mouse skeletal muscle
Albadrani, H. M., Ammar, T. A. R. A., Rajgara, R. F., Bäder, M., Wiper‐Bergeron, N., & Renaud, J. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00271.2021 · Cited by 3
Proença, A. B., Alexandre‐Santos, B., Giori, I. G., Alex‐Marques, J. S. F., Machado‐Santos, C., Machado, M. V. R., Magliano, D. C., da Nóbrega, A. C. L., & Frantz, E. D. C. (2024) · Physiological Reports · doi:10.14814/phy2.16025 · Cited by 3
“…et al., 2018; Sepúlveda-Fragoso et al., 2021)/MasR arm has antiapoptotic effects, and it also reduces the expression of muscle atrophy F-box gene (Atrogin-1/MAFbx) and muscle RING-68 finger protein (MuRF-1) induced by Ang II in myotubes (Cabello-Verrugio et al., 2017; Cisternas et al., 2015).”
BackgroundAlbadrani, H. M., Ammar, T. A. R. A., Bäder, M., & Renaud, J. (2021) · The Journal of General Physiology · doi:10.1085/jgp.201912556 · Cited by 3
“However, at a lower dose of 100 ng/kg/d, Ang 1-7 significantly reduced skeletal muscle at rophy and apoptosis induced by endotoxin, Ang II, TGF-ß, or disuse (Cisternas et al., 2015; Meneses et al., 2015; Morales et al., 2015b; A.brigo et al., 2016; Morales et al., 2016) while it restores muscle strength in dystrophic…”
BackgroundInfluentialAngiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV
Deminice, R., Cella, P. S., Borsari, A. L., Padilha, C. S., & Oliveira, V. H. F. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70016 · Cited by 2
“Recently, studies have demonstrated that Ang1–7 protects locomotor muscles against atrophy due to prolonged inactivity or high circulating levels of Ang-II [32, 33].”
Awad, A. S., El-Din, M. N., & Kamel, R. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.05.004 · Cited by 1
“On the other hand, Ang (1–7) has shown favorable effects against various skeletal muscle abnormalities through its action on Mas receptors (Cabello-Verrugio et al., 2015, Cisternas et al., 2015).”
Vecchiatto, B. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.100.2019.tde-01102019-220112 · Cited by 1
Szymaszkiewicz, K., Szymaszkiewicz, A., Kowalczyk, E., & Wiktorowska‐Owczarek, A. (2019) · Farmacja Polska · doi:10.32383/farmpol/116273
“[26] opisali, że szkodliwy wpływ Ang II na mięśnie szkieletowe (porównano średnicę włókien”
Nguyen, B. L., Yoshihara, T., Deminice, R., Lawrence, J., Ozdemir, M., Hyatt, H. W., & Powers, S. K. (2021) · Sports Medicine and Health Science · doi:10.1016/j.smhs.2021.06.003
Albadrani, H. (2021) · uO Research (University of Ottawa) · doi:10.20381/ruor-26759
de Moura, S. S., Mendes, A. T. P., Júnior, F. D. A. D. M., Totou, N. L., Coelho, D. B., de Oliveira, E. C., Motta‐Santos, D., Santos, R. A. S., & Becker, L. K. (2021) · Research Square · doi:10.21203/rs.3.rs-151769/v1
de Moura, S. S., Mendes, A. T. P., Júnior, F. D. A. D. M., Totou, N. L., Coelho, D. B., de Oliveira, E. C., Motta‐Santos, D., Santos, R. A. S., & Becker, L. K. (2020) · Research Square · doi:10.21203/rs.3.rs-58840/v1
Ang-(1-7) Protects Skeletal Muscle Function in Aged MicePreprint
Huang, X., Song, J., Jiang, Y., Yang, X., Cao, L., Xiao, C., Li, S., Dong, B., & Li, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-294231/v1
Therapeutic Efficacy of HPβ‐CD‐Angiotensin‐(1‐7) Oral Formulation in Muscle Injury Recovery in Rat
Totou, N. L., Rocha, A. M. S., de Moura, S. S., Pereira, C. H., Coelho, F. S., Dophine, D. D., Coelho, D. B., de Oliveira, E. C., Santos, R. A. S., Becker, L. K., et al. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70851
Skeletal Muscle Dysfunction in Heart Failure
Challa, A. A., Pandey, A., Brubaker, P. H., Kitzman, D. W., Bozkurt, B., & Kalra, D. K. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103353
Metadata
- Authors
- Cisternas, F., Morales, M. G., Meneses, C., Simon, F., Brandan, E., Abrigo, J., Vazquez, Y., & Cabello-Verrugio, C.
- Affiliations
- Universidad Andrés Bello (CL)
- Laboratorio de Fisiopatología Integrativa, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas & Facultad de Medicina, Universidad Andres Bello, Santiago, Chile
- Pontificia Universidad Católica de Chile (CL)
- Laboratorio de Biología y Fisiopatología Molecular, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas & Facultad de Medicina, Universidad Andres Bello, Santiago, Chile
- Corresponding author
- Cisternas, Franco
- Meneses, Carla
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2014-11-05
- Volume
- 128
- Issue
- 5
- Pages
- 307-319
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W1974759520
- Cited by
- 83
- References
- 69
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 14 · 2020: 11 · 2019: 11 · 2018: 8 · 2017: 6 · 2016: 7 · 2015: 8
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
- americanae.aecid.es
- Licence
- other-oa
- Locations
- Clinical Science (publishedVersion)
- PubMed (publishedVersion)
- Americanae (AECID Library) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Keywords
- angiotensin-(1-7), angiotensin II, skeletal muscle atrophy, Mas receptor, Akt phosphorylation, atrogin-1, MuRF1, myosin heavy chain degradation, ubiquitin ligase, muscle atrophy, gastrocnemius, MK-2206, C2C12 myotubes
- MeSH terms
- Tripartite Motif Proteins, Proto-Oncogene Mas, Angiotensin I, Angiotensin II, Animals, Cell Line, Gene Expression Regulation, Male, Mice, Inbred C57BL, Muscle Proteins, Muscular Atrophy, Peptide Fragments, Phosphorylation, Proto-Oncogene Proteins, Signal Transduction, Muscle, Skeletal, Muscle Fibers, Skeletal, Myosin Heavy Chains, Receptors, G-Protein-Coupled, Ubiquitin-Protein Ligases, SKP Cullin F-Box Protein Ligases, Proto-Oncogene Proteins c-akt, Muscle Strength
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.